BridgeBio(BBIO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $154.2 million, consisting of $146 million from Attruby net product revenue, compared to $5.9 million for the same period last year, reflecting a significant increase of $148.3 million [31][32] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, marking an increase of $280.2 million [32][34] - Cash burn for the year was $446 million, with a decline in cash burn noted in Q4 relative to Q3, driven by rising revenues and improving operating leverage [6][10] Business Line Data and Key Metrics Changes - Attruby's net product revenue for Q4 was $146 million, contributing to a total of $362.4 million for the year, reflecting broad-based growth across market segments [23][31] - New patient growth for Attruby accelerated to 7,804 new patient starts in Q4, indicating strong commercial momentum [23][24] Market Data and Key Metrics Changes - Attruby achieved over 25% market share in the ATTR cardiomyopathy market as of December 31, 2025, with continued growth in unique patient prescriptions [17][23] - The company anticipates that its pipeline will begin generating cash in late 2027 and become a cash generation engine by 2028, projecting over $600 million in profit by that year [7][8] Company Strategy and Development Direction - The company is transitioning from a cash-consuming business to one that generates significant cash flows, with a focus on launching three additional products in late 2026 or early 2027 [5][11] - The strategy emphasizes establishing a best-in-class commercial engine for genetic disease therapies, with a commitment to R&D efficiency and organic growth rather than M&A [52][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the intrinsic value of the company, despite recent stock price volatility, attributing the disconnect to uncertainty surrounding the Tafamidis IP situation [10][80] - The company is focused on executing against its milestones and believes that its fundamentals have strengthened commercially, clinically, and strategically [10][11] Other Important Information - The company ended the year with a cash position of $587.5 million and completed the issuance of $632.5 million in convertible notes, providing significant cash runway for future operations [35] - Management highlighted the importance of differentiating Attruby's clinical profile and market positioning, asserting that it remains confident in its long-term value despite potential generic competition [80] Q&A Session Summary Question: What are the key drivers behind Attruby's consistent growth despite competitors slowing down? - Management attributed growth to a strong field team, superior clinical data, and a disciplined focus on patient and healthcare professional needs [40][41] Question: When will significant real-world data be available to establish clinical differentiation? - Management indicated that real-world evidence should be available by the end of the calendar year, focusing on early impact and specific patient populations [50] Question: How does the company plan to use incremental free cash flow in the future? - The company intends to reinvest in R&D and potentially consider share buybacks or dividends if unable to capture the intrinsic value of its assets [53] Question: What is the competitive landscape for infigratinib compared to other therapies? - Management believes infigratinib is best-in-class, with a favorable balance of efficacy and safety, setting a new standard in achondroplasia treatment [71] Question: What is the company's perspective on Tafamidis IP and its impact on Attruby? - Management views the Tafamidis IP debate as a sideshow, asserting that Attruby's clinical differentiation will sustain its market position regardless of generic competition [80]